H Mengel
Overview
Explore the profile of H Mengel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daugschies A, Agneessens J, Goossens L, Mengel H, Veys P
Vet Parasitol
. 2007 Sep;
149(3-4):199-206.
PMID: 17850970
A multicenter field efficacy study was performed in six farms located in Belgium, France and Germany with a history of suspected coccidiosis outbreaks and the proven presence of Eimeria bovis...
2.
Sogaard B, Mengel H, Rao N, Larsen F
J Clin Pharmacol
. 2005 Nov;
45(12):1400-6.
PMID: 16291715
The pharmacokinetics of escitalopram (S-citalopram) and its principal metabolite, S-demethylcitalopram (S-DCT), were investigated after intravenous and oral administration to healthy subjects. After intravenous infusion of escitalopram, the mean systemic clearance...
3.
Mundt H, Bangoura B, Mengel H, Keidel J, Daugschies A
Parasitol Res
. 2005 Oct;
97 Suppl 1:S134-S142.
PMID: 16228270
The efficacy of metaphylactic treatment with toltrazuril (Baycox 5% suspension) against natural infections with Eimeria bovis and/or Eimeria zuernii in calves was investigated. The study was conducted with 208 calves...
4.
Thal L, Forrest M, Loft H, Mengel H
Neurology
. 2000 Feb;
54(2):421-6.
PMID: 10668706
Objective: To evaluate the therapeutic effect of the selective muscarinic receptor m1 partial agonist, m2 antagonist, Lu25-109-a compound that directly stimulates muscarinic cholinergic receptors-in patients with probable AD. Methods: A...
5.
Sramek J, Forrest M, Mengel H, Jhee S, Hourani J, Cutler N
Life Sci
. 1998 Mar;
62(3):195-202.
PMID: 9488097
Lu 25-109 is a functionally selective partial M1 agonist with M2/M3 antagonist properties. This double-blind, placebo-controlled, two-part, inpatient bridging study was designed to evaluate the safety and tolerability of multiple...
6.
Richens A, Chadwick D, Duncan J, Dam M, Gram L, Mikkelsen M, et al.
Epilepsy Res
. 1995 May;
21(1):37-42.
PMID: 7641674
Tiagabine is a new antiepileptic drug which acts by a novel mechanism, inhibiting the reuptake of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) into neurons and glia. A double-blind, placebo-controlled, crossover...
7.
8.
Mengel H
Epilepsia
. 1994 Jan;
35 Suppl 5:S81-4.
PMID: 8039477
Tiagabine (TGB), a specific gamma-aminobutyric acid (GABA)-uptake inhibitor, is a potential new antiepileptic drug with a novel mechanism of action. In animal models of epilepsy as well as in a...
9.
Andersen B, Mikkelsen M, Vesterager A, Dam M, Kristensen H, Pedersen B, et al.
Epilepsy Res
. 1991 Nov;
10(2-3):201-4.
PMID: 1840138
A single-blind, placebo-controlled, cross-over trial investigating possible interactions between paroxetine, a serotonin re-uptake inhibitor, and carbamazepine (CBZ), valproate (VPA) and phenytoin (PHT) was carried out in 20 outpatients with epilepsy....
10.
Dalhoff K, Almdal T, Bjerrum K, Keiding S, Mengel H, Lund J
Eur J Clin Pharmacol
. 1991 Jan;
41(4):351-4.
PMID: 1839532
In a 14-day multiple-dose study the pharmacokinetics of paroxetine was investigated in 12 patients with alcoholic cirrhosis and in 6 subjects without liver disease. The dose of 20-30 mg paroxetine...